Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | NDAQ

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BioLineRx Ltd. A biopharmaceutical firm developing and commercializing therapies for oncology and rare diseases.	United States of America	BLRX
BIOMARIN PHARMACEUTICAL INC Develops and commercializes therapies for rare, life-threatening genetic diseases.	United States of America	BMRN
BioMaxima S.A. Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.	Poland	BMX
Biomea Fusion, Inc. Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.	United States of America	BMEA
BIOMERICA INC Develops diagnostic tests for GI, inflammatory diseases, and diabetes for lab and at-home use.	United States of America	BMRA
bioMérieux Provides in vitro diagnostic solutions for clinical and industrial microbiology.	France	BIM
BiomX Inc. Develops phage therapies to target harmful bacteria in chronic diseases like cystic fibrosis.	United States of America	PHGE
BioNTech SE Pioneering mRNA immunotherapies and vaccines to combat cancer and infectious diseases.	United States of America	BNTX
BioPorto IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.	Denmark	BIOPOR
BioRestorative Therapies, Inc. A clinical-stage company developing stem cell therapies for pain, metabolic disorders, and aesthetics.	United States of America	BRTX